Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain | Current Treatment: Physician Insights | US | 2017

Market Outlook

Osteoarthritis (OA) pain is an extremely prevalent type of chronic pain, affecting more than 30 million individuals in the United States, and is the second-largest segment of the overall chronic pain market. Treatment of OA pain is dominated by cost-effective generic treatments, in addition to costly abuse-deterrent reformulations of opioid analgesics and new combinations of existing analgesics that attempt to mitigate side effects; no truly novel or mechanism-based therapies are currently available. The key drug classes prescribed to treat OA pain, nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, are associated with a host of side effects including gastrointestinal, cardiovascular, and/or abuse risks. As such, treatment of this indication can be challenging for physicians because existing therapies are frequently inadequate in achieving long-term analgesia in many patients.

Questions Answered

  • How is OA pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
  • What impact have the recent launches of new analgesics such as Iroko’s Vivlodex and Purdue’s Hysingla ER had on physician prescribing behavior for OA pain?
  • What factors drive switching between or discontinuation of select analgesics (e.g., Depomed’s Nucynta ER, Horizon’s Vimovo, Pfizer’s Embeda)?
  • How does patient risk for abuse/history of abuse influence physicians’ prescribing of opioid analgesics for OA pain?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment paths, prescribing behaviors, and the factors and perceptions driving brand usage so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…